₹ 0.6 Cr
Volume transacted
3.9 K
stocks traded
Last Updated time: 26 Jul 9.00 AM
Caplin Point Laboratories Ltd
NSE: CAPLIPOINT
PE
25
Last updated : 26 Jul 9.00 AM
The P/E Ratio of Caplin Point Laboratories Ltd is 25 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Caplin Point Laboratories Ltd changed from 17.2 on March 2019 to 12 on March 2023 . This represents a CAGR of -6.95% over 5 years. a1#The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 1504 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3042 crore on March 2019 to ₹ 4529 crore on March 2023 . This represents a CAGR of 8.28% over 5 years. a1#The Revenue of Caplin Point Laboratories Ltd changed from ₹ 360.27 crore to ₹ 470.57 crore over 8 quarters. This represents a CAGR of 14.29% a1#The EBITDA of Caplin Point Laboratories Ltd changed from ₹ 116.12 crore to ₹ 162.58 crore over 8 quarters. This represents a CAGR of 18.33% a1#The Net Pr of Caplin Point Laboratories Ltd changed from ₹ 86.31 crore to ₹ 121.23 crore over 8 quarters. This represents a CAGR of 18.52% a1#The Dividend Payout of Caplin Point Laboratories Ltd changed from 11.23 % on March 2019 to 14.58 % on March 2023 . This represents a CAGR of 5.36% over 5 years. a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Period | |
---|---|
Mar '19 | 17.2 |
Mar '20 | 9.9 |
Mar '21 | 12.6 |
Mar '22 | 17.2 |
Mar '23 | 12 |
Market Cap
₹ 11,433 Cr
EPS
₹ 60.1
P/E Ratio (TTM) *
25.0
P/B Ratio (TTM) *
4.9
Day’s High
₹ 1517.75
Day’s Low
₹ 1500.0
DTE *
0.0
ROE *
19.7
52 Week High
₹ 1617.8
52 Week Low
₹ 838.7
ROCE *
24.3
* All values are consolidated
Last Updated time: 26 Jul 9.00 AM
* All values are consolidated
Last Updated time: 26 Jul 9.00 AM
Caplin Point Laboratories Ltd
NSE: CAPLIPOINT
PRICE
₹ 1504.2
-16.50 (-1.09%)
Last updated : 25 Jul 15:30
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
* All values are in Rupees
Strength
2
S
Weakness
1
W
Opportunity
0
O
Threats
0
T
Revenue
Profitability
Affordability
Liquidity
Dividend
Market Value
₹ 11,433
Asset Value
₹ 1,423
7.0 X
Value addition
* All values are in Rupees
Company Name | PE | Market Cap (INR Cr.) |
---|---|---|
Caplin Point Laboratories Ltd | 25 | 11,433 |
Sun Pharmaceuticals Industries Ltd | 40 | 399,537 |
Zydus Lifesciences Ltd | 31 | 121,312 |
Cipla Ltd | 28 | 121,120 |
Divis Laboratories Ltd | 75 | 120,782 |
Dr Reddys Laboratories Ltd | 20 | 114,348 |
Earnings
₹457 Cr
25.0 X
PE Ratio
Market Cap
₹11433Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Earnings
₹457 Cr
25.0 X
PE Ratio
Market Cap
₹11433Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 3043 |
Mar '20 | 2136 |
Mar '21 | 3057 |
Mar '22 | 5153 |
Mar '23 | 4529 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 360 |
Sep '22 | 376 |
Dec '22 | 386 |
Mar '23 | 401 |
Jun '23 | 407 |
Sep '23 | 431 |
Dec '23 | 453 |
Mar '24 | 471 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | 116 |
Sep '22 | 122 |
Dec '22 | 124 |
Mar '23 | 135 |
Jun '23 | 139 |
Sep '23 | 158 |
Dec '23 | 159 |
Mar '24 | 163 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | 86 |
Sep '22 | 92 |
Dec '22 | 97 |
Mar '23 | 101 |
Jun '23 | 104 |
Sep '23 | 116 |
Dec '23 | 120 |
Mar '24 | 121 |
* All values are a in ₹crore
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 11 |
Mar '20 | 10 |
Mar '21 | 15 |
Mar '22 | 16 |
Mar '23 | 15 |
* All values are a in %
Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil). The company came out with a public issue in Nov.'94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories, US, for specific products, with a 30% buyback arrangement. It also imports bio-technological products to market them in India. The company has established a trading branch in Nairobi, Kenya, to sell its products in East Africa. It has also established a warehouse in Miami, US, by entering into a marketing tie-up with Lockett Medical Corporation, US.During the year 2015, the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Company's share in LLP has increased to 99.90% in Argus Salud Pharma LLP.In October 2016, the Company had subdivided the shares from the face value of Rs 10/- to Rs 2/- and upon sub-division, the members were issued five equity shares of Rs 2/- each in lieu of one equity share of Rs 10/- each. After sub-division, the paid up capital of Rs15,11,00,000 was sub- divided into 7,55,50,000 equity shares of Rs 2/- each.As on 31 March 2018, the Company has three subsidiaries, viz Argus Salud Pharma LLP, Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia. During the year 2019, the Company transferred its regulated markets injectable business which, inter-alia includes US FDA approved injectable plant and Department of Science and Industrial Research (DSIR) recognised R& D Units CP4 and CP 5 to Caplin Steriles Limited, a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31, 2018. In FY2019, the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and F-Prime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares (CCPS), which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms. During FY 2019, the Company formed a Joint Venture, Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China, which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China, India, Europe and Latin America. In FY'21, Company acquired four channel partners in Latin America, strengthening control on marketing, distribution and supply chain. It launched an e-commerce website named QueTenX', a part of the 10X healthcare portal, transforming credit sales into cash, enhancing an analysis of demand and supply patterns and replenishment stocks through technology tools. It deepened capabilities by stocking essential products at warehouses during the COVID-19 months. It commissioned a DGCI-approved CRO facility and captive API development kilo lab to facilitate backward integration. It received approvals for nine of 18 ANDAs filed (six for Caplin Steriles); five products launched; the next four to be launched in the near future. It embarked on a pipeline of 15 ANDAs to be filed within 24 months with an addressable market size of USD 1.95 billion. It completed ab scale batches for 17 products for US (by Caplin's API division) and trebled capacity of the manufacturing facility. The Company received four ANDA approvals since January 2021, increasing approved ANDAs to 15 (ten under Caplin's name and five through partners). It launched eight products in US; four products are ready for launch and three are likely to be launched before December 2021. It received large tender orders worth $18 million in two markets and has started R&D for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress as such. The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs. 140 Crore and will include 2 Vial lines, one Lyophilizer line, one Pre- filled syringe line and provision to add another Pre-mix bag line. During the year 2022-23, the Company had disposed its entire investment in Caplin Point Laboratories Colombia SAS to Caplin Point Far East Limited - Hong Kong, a wholly - owned subsidiary of the Company and effective from March 28, 2023, Caplin Point Laboratories Colombia SAS ceased to be a subsidiary but became a step-down subsidiary. In 2023, Caplin doubled its capacity to produce Softgel formulation at its Puducherry facility. The Company implemented the latest, S4 hana, version of SAP - enterprise resource planning system. It developed new line of products i.e. Oncology. It completed 4 complex products Exhibit Batches, which includes 3 Injectables and 1 Ophthalmic; launched co-labelled products in the US, for 4 approved products. It launched 23 new products in Central America which has contributed to $2.4m dollars in sale. The second line of production in Softgel dosage was completed in 2023. It acquired an API plant in Visakhapatnam, Andhra Pradesh.
Caplin Steriles receives USFDA approval for Ephedrine Sulfate injection
Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories, has been gran...
Read more
19 Jul 202411:27
Caplin Point Labs subsidiary gets US FDA nod for Ephedrine Sulfate Injection
The approved ANDA is a generic therapeutic equivalent version of the reference listed drug...
Read more
19 Jul 202411:01
Caplin Point Laboratories allots 1,400 equity shares under ESOP
Caplin Point Laboratories has allotted 1,400 equity shares under ESOP on 16 July 2024. Pow...
Read more
16 Jul 202419:21
Caplin Point Laboratories allots 68,550 equity shares under ESOS
Caplin Point Laboratories has allotted 68,550 equity shares under ESOS on 19 June 2024. Po...
Read more
19 Jun 202414:17
Caplin Steriles receives USFDA approval for Phenylephrine hydrochloride Ophthalmic solution
Caplin Steriles (Caplin), a subsidiary of Caplin Point Laboratories has been granted final...
Read more
24 May 202412:26
Board of Caplin Point Laboratories recommends Interim Dividend
Caplin Point Laboratories announced that the Board of Directors of the Company at its meet...
Read more
16 May 202414:24
FAQs for PE of Caplin Point Laboratories Ltd
What is Caplin Point Laboratories Ltd current share price?
Is Caplin Point Laboratories Ltd a good investment?
What are Caplin Point Laboratories Ltd's total net assets?
Is Caplin Point Laboratories Ltd making a profit or loss?
Unlimited trading at just
Rs. 199